Interleukin

Switching from a TNF inhibitor to upadacitinib leads to significantly better outcomes in rheumatoid arthritis vs. cycling TNF inhibitors or switching to another mechanism of action, according to data published in Advances in Therapy.

The most efficacious targeted therapies for VEXAS syndrome are Janus kinase inhibitors and interleukin-6 inhibitors, while IL-1 and TNF blockers are less effective, according to data published in the Annals of the Rheumatic Diseases.

Almirall has entered into an exclusive license agreement with Novo Nordisk to develop and commercialize NN-8828 for autoimmune and inflammatory dermatological diseases, according to a company press release.

Patients with severe prurigo nodularis treated with nemolizumab vs. placebo experienced changes in signaling pathways and biomarkers that affect inflammatory, neural and epithelial regulation, according to a multicenter cohort study.

WASHINGTON — Patients with asthma experienced fast and substantial reductions in fractional exhaled nitric oxide with the SAR443765 bifunctional NANOBODY molecule, which blocks thymic stromal lymphopoietin and IL-13, according to a study.

DESTIN, Fla. — Incomplete understanding of axial spondyloarthritis disease process poses challenges for treatment decision making, according to a presenter at the 2023 Congress of Clinical Rheumatology-East.

The pro-inflammatory protein IL-3 appeared to regulate the burden of allergic asthma by inducing T regulatory cell response and reducing the proliferation of type 2 innate lymphoid cells, according to a study in Frontiers in Immunology.

Itaconate and its derivative 4-octyl itaconate inhibit the Januse kinase 1 immune protein, which has implications for potential severe asthma treatment, according to a study published in Cell Metabolism.

Bimekizumab demonstrates statistically significant improvement over placebo in the proportion of patients achieving Assessment of Spondyloarthritis International Society 40 response at week 16, according to interim results released by UCB.

Increased interleukin‐1Ra and IL‐8 serum levels, and other biomarker profiles, “clearly separate” COVID-19 from macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis, according to data published in Arthritis & Rheumatology.